Brecanavir

Today, Brecanavir is a topic of great interest and relevance in today's society. With the advancement of technology and globalization, Brecanavir has become a topic that covers different aspects of daily life, from the way we communicate to the way we carry out our daily activities. Brecanavir is a concept that has captured the attention of academics, professionals and the general public, due to its impact in various areas, such as economy, politics, health, education and the environment. In this article, we will explore the meaning and importance of Brecanavir, as well as its implications in today's society.

Brecanavir
Clinical data
ATC code
  • none
Identifiers
  • furan-3-yl] N-phenyl]butan-2-yl]carbamate
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC33H41N3O10S2
Molar mass703.82 g·mol−1
3D model (JSmol)
  • O=S(=O)(c2ccc1OCOc1c2)N(CC(C)C)C(O)(NC(=O)O34CCO4OC3)Cc6ccc(OCc5nc(sc5)C)cc6
  • InChI=1S/C33H41N3O10S2/c1-20(2)14-36(48(39,40)25-8-9-29-30(13-25)45-19-44-29)15-28(37)27(35-33(38)46-31-17-43-32-26(31)10-11-41-32)12-22-4-6-24(7-5-22)42-16-23-18-47-21(3)34-23/h4-9,13,18,20,26-28,31-32,37H,10-12,14-17,19H2,1-3H3,(H,35,38)/t26-,27-,28+,31-,32+/m0/s1 checkY
  • Key:JORVRJNILJXMMG-OLNQLETPSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Brecanavir (INN; codenamed GW640385) is a protease inhibitor which has been studied for the treatment of HIV.[1]

In December 2006, its developer, GlaxoSmithKline discontinued further development because of insurmountable issues regarding formulation.[2]

See also

References

  1. ^ Hazen R, Harvey R, Ferris R, et al. (September 2007). "In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV". Antimicrob. Agents Chemother. 51 (9): 3147–54. doi:10.1128/AAC.00401-07. PMC 2043237. PMID 17620375.
  2. ^ "GlaxoSmithKline discontinues clinical development of investigational protease inhibitor brecanavir (640385)" (Press release). GlaxoSmithKline. 2006-12-18. Archived from the original on 2008-12-03. Retrieved 2008-06-11.


Stub icon

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.